ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01152593
Recruitment Status : Unknown
Verified June 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : June 29, 2010
Last Update Posted : June 29, 2010
Sponsor:
Information provided by:
Hillel Yaffe Medical Center

Brief Summary:
The investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.

Condition or disease Intervention/treatment Phase
Surgical Wound Infection Cesarean Section Staphylococcus Aureus Drug: Mupirocin Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Study Start Date : July 2010
Estimated Primary Completion Date : July 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Intranasal Mupirocin Drug: Mupirocin
Intranasal cream given to patient after confirmation of colonization



Primary Outcome Measures :
  1. Reduction of the incidence of surgical site infections after cesarean section [ Time Frame: Four years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Women assigned to undergo cesarean section

Exclusion Criteria:

  • All others

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152593


Locations
Israel
Hillel Yaffe Medical Center Not yet recruiting
Hadera, Israel, 38100
Contact: Gai Shrem, MD       gais@hy.health.gov.il   
Principal Investigator: Gai Shrem, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center

Responsible Party: Gai Shrem, MD, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01152593     History of Changes
Other Study ID Numbers: HYMC0033-10
First Posted: June 29, 2010    Key Record Dates
Last Update Posted: June 29, 2010
Last Verified: June 2010

Additional relevant MeSH terms:
Infection
Wound Infection
Surgical Wound
Surgical Wound Infection
Wounds and Injuries
Postoperative Complications
Pathologic Processes
Mupirocin
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action